Annual Report 2018
Annual Report 2018
Sydney, Aug 30, 2018 AEST (ABN Newswire) - Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities (the Group) for the financial year ended 30 June 2018.

Principal activities

Regeneus is an ASX-listed clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

The company is focused on unlocking value in its clinical-stage human and animal pipeline products through generating positive clinical data, technology development and partnering.

Review of operations

During the year, Regeneus achieved significant milestones positioning the Group for future growth including:

AGC licensing of Progenza

- AGC Inc. have the exclusive rights to manufacture Progenza for Japan. The ongoing collaboration is progressing well with AGC establishing a cell production facility in Japan

Progenza human clinical STEP trial published

- Progenza STEP trial positive results were published in the well-respected Journal of Translational Medicine

Partnering and technology development

- Advancing partnering discussions for clinical development and commercialisation of Progenza in Japan

- Patent allowed for Progenza in US complementing patents in Australia and Japan

- Progenza granted ATMP status in Europe

Clinical trials

- RGSH4K ACTIVATE trial met primary endpoints of safety with promising signs of immune stimulation

- CryoShot pre-pivotal trial of the allogeneic off-the-shelf stem cells for canine osteoarthritis at University of Pennsylvania continues to be recruited

- Kvax trial of the autologous canine cancer vaccine for lymphoma at Small Animal Specialist Hospital in Sydney continues to be recruited

To view the full report, please visit:
http://abnnewswire.net/lnk/370VC5MB

To view FY18 Results and Business Update Presentation, please visit:
http://abnnewswire.net/lnk/5AGU610O


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

      


Contact

Sandra McIntosh
Company Secretary and Investor Relations
T: +61-2-9499-8010
E: investors@regeneus.com.au
W: www.regeneus.com.au



Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 48) (Last 30 Days: 224) (Since Published: 3538) 
ANALYTICS: LOGIN HERE

Regeneus Ltd NEWS: RECENT VISITS (9057)

Research Report

Social Media